earnings
confidence high
sentiment positive
materiality 0.70
ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)
ABVC BIOPHARMA, INC.
2025-Q1 EPS reported
-$0.06
- Revenue surged 234% to $509,589 driven by licensing milestones.
- Net loss improved to $4.90M from $7.79M; EPS improved 77% to $(0.42).
- Operating expenses reduced 21% to $5.21M, R&D down 83%, SG&A down 58%.
- Stock-based compensation increased to $2.77M from $0.19M to preserve cash.
- Remaining milestone potential of up to $18.3M under existing licensing deals.